Citations

Clear

572 citation(s) found for "Silva, P".

Clinical Features and Outcomes Associated with Angioedema in the Emergency Department
Sandefur, Benjamin J. , Silva, Lucas Oliveira J. e , Lohse, Christine M. , Goyal, Kiran A., Barbara, David W. , Castañeda-Guarderas, Ana, Liu, Xiaowei , E Silva, Lucas Oliveira J, Liu, Xiao-Wei, Campbell, Ronna L. , Oliveira J E Silva, Lucas

Mayo Clinic

Western Journal of Emergency Medicine | September 9, 2019 | Volume: 20 | Issue: 5 | Pages: 760-769

10.5811/westjem.2019.6.42852 | PMID 31539333 Get It

Pediatric Burn Treatment Using Tilapia Skin as a Xenograft for Superficial Partial-Thickness Wounds: A Pilot Study
Júnior, Edmar Maciel Lima , Moraes, Manoel Odorico de , Forte, Antonio J. , Costa, Bruno Almeida , Fechine, Francisco Vagnaldo , Alves, Ana Paula Negreiros Nunes , Moraes, Maria Elisabete Amaral de , Rocha, Marina Becker Sales , Júnior, Francisco Raimundo Silva, Soares, Maria Flaviane Araújo do Nascimento, Martins, Camila Barroso , Mathor, Mônica Beatriz , Forte, Antonio Jorge , Júnior, Francisco Raimundo Silva, Bezerra, Alane Nogueira

Mayo Clinic

Journal of Burn Care & Research | August 26, 2019 | Volume: 41 | Issue: 2 | Pages: 241-247

10.1093/jbcr/irz149 | PMID 31504615 Get It

Abstract This study aims to evaluate the efficacy of Nile tilapia skin as a xenograft for the treatment of partial-thickness burn wounds in children. This is an open-label, monocentric, randomized phase II pilot study conducted in Fortaleza, Brazil. The study population consisted of 30 children between the ages of 2 and 12 years with superficial “partial-thickness” burns admitted less than 72 hours from the thermal injury. In the test group, the tilapia skin was applied. In the control group, a thin layer of silver sulfadiazine cream 1% was applied. Tilapia skin showed good adherence to the wound bed, reducing the number of dressing changes required, the amount of anesthetics used, and providing benefits for the patients and also for healthcare professionals, by reducing the overall work load. The number of days to complete burn wound healing, the total amount of analgesics required throughout the treatment, burn improvement on the day of dressing removal, and pain throughout the treatment were similar to the conventional treatment with silver sulfadiazine. Thus, tilapia skin can be considered an effective and low-cost extra resource in the therapeutic arsenal of pediatric superficial partial thickness burns.
Five‐Year Outcome of Operative and Nonoperative Management of Meniscal Tear in Persons Older Than Forty‐Five Years
Katz, Jeffrey N. , Shrestha, Swastina , Marx, Robert G. , Mandl, Lisa A. , Levy, Bruce A. , MacFarlane, Lindsey A. , Silva, Genevieve S. , Investigators, METEOR, Brophy, Robert H. , Losina, Elena , MacFarlane, Lindsey A , Collins, Jamie E , Brophy, Robert H. , Katz, Jeffrey N , Losina, Elena , Jones, Morgan H. , Marx, Robert G. , Spindler, Kurt P , Investigators, METEOR

Mayo Clinic

Arthritis & Rheumatology | August 20, 2019 | Volume: 72 | Issue: 2 | Pages: 273-281

10.1002/art.41082 | PMID 31429198 Get It

ObjectiveTo determine the 5‐year outcome of treatment for meniscal tear in osteoarthritis.MethodsWe examined 5‐year follow‐up data from the Meniscal Tear in Osteoarthritis Research trial (METEOR) of physical therapy versus arthroscopic partial meniscectomy. We performed primary intent‐to‐treat (ITT) and secondary as‐treated analyses. The primary outcome measure was the Knee Injury and Osteoarthritis Outcome Score (KOOS) pain scale; total knee replacement (TKR) was a secondary outcome measure. We used piecewise linear mixed models to describe change in KOOS pain. We calculated 5‐year cumulative TKR incidence and used a Cox model to estimate hazard ratios (HRs) for TKR, with 95% confidence intervals (95% CIs).ResultsThree hundred fifty‐one participants were randomized. In the ITT analysis, the KOOS pain scores were ~46 (scale of 0 [no pain] to 100 [most pain]) at baseline in both groups. Pain scores improved substantially in both groups over the first 3 months, continued to improve through the next 24 months (to ~18 in each group), and were stable at 24–60 months. Results of the as‐treated analyses of the KOOS pain score were similar. Twenty‐five participants (7.1% [95% CI 4.4–9.8%]) underwent TKR over 5 years. In the ITT model, the HR for TKR was 2.0 (95% CI 0.8–4.9) for subjects randomized to the arthroscopic partial meniscectomy group, compared to those randomized to the physical therapy group. In the as‐treated analysis, the HR for TKR was 4.9 (95% CI 1.1–20.9) for subjects ultimately treated with arthroscopic partial meniscectomy, compared to those treated nonoperatively.ConclusionPain improved considerably in both groups over 60 months. While ITT analysis revealed no statistically significant differences following TKR, greater frequency of TKR in those undergoing arthroscopic partial meniscectomy merits further study.
Opioid-Induced Esophageal Dysfunction: Differential Effects of Type and Dose
Snyder, Diana L. , Horsley‐Silva, Jennifer L. , Lacy, Brian E. , Vela, Marcelo F. , Horsley-Silva, Jennifer, Crowell, Michael D. , Ravi, Karthik

Mayo Clinic

American Journal of Gastroenterology | August 9, 2019 | Volume: 114 | Issue: 9 | Pages: 1464-1469

10.14309/ajg.0000000000000369 | PMID 31403963 Get It

OBJECTIVE: Data regarding opioid effects on esophageal function are limited. We previously demonstrated an association between chronic opioid use and esophageal motor dysfunction characterized by esophagogastric junction outflow obstruction, distal esophageal spasm, achalasia type III, and possibly Jackhammer esophagus. Our aim was to characterize the influence of different opioids and doses on esophageal dysfunction. METHODS: Retrospective review of 225 patients prescribed oxycodone, hydrocodone, or tramadol for >3 months, who completed high-resolution manometry from 2012 to 2017. Demographic and manometric data were extracted from a prospectively maintained motility database. Frequency of opioid-induced esophageal dysfunction (OIED, defined as distal esophageal spasm, esophagogastric junction outflow obstruction, achalasia type III, or Jackhammer esophagus on high-resolution manometry, was compared among different opioids. The total 24-hour opioid doses for oxycodone, hydrocodone, and tramadol were converted to a morphine equivalent for dose effect analysis. RESULTS: OIED was present in 24% (55 of 225) of opioid users. OIED was significantly more prevalent with oxycodone or hydrocodone use compared with tramadol (31% vs 28% vs 12%, P = 0.0162), and for oxycodone alone vs oxycodone with acetaminophen (43% vs 21%, P = 0.0482). There was no difference in OIED for patients taking hydrocodone alone vs hydrocodone with acetaminophen. Patients with OIED were taking a higher median 24-hour opioid dose than those without OIED (45 vs 30 mg, P = 0.058). DISCUSSION: OIED is more prevalent in patients taking oxycodone or hydrocodone compared with tramadol. There is greater likelihood of OIED developing with higher doses. Reducing the opioid dose or changing to tramadol may reduce OIED in opioid users.
Abstract 3132: Immune regulatory gene expression and clinical outcome in the NeoALTTO trial
Solinas, Cinzia , Silva, Pushpamali De , Venet, David , Werner, Olena, Peña, Lorena de la, Lang, Istvan, Huober, Jens , Küemmel, Sherko , Salgado, Roberto , Piccart, Martine , Fumagalli, Debora , De Silva, Pushpamali , Garaud, Soizic , Gu‐Trantien, Chunyan , Hilbers, Florentine , Azambuja, Evandro de , Dueck, Amylou C. , Cosimo, Serena Di , Lang, Istvan, Denkert, Carsten , Sotiriou, Christos P. , Willard‐Gallo, Karen

Mayo Clinic

Cancer Research | August 7, 2019 | Volume: 79 | Issue: 13_Supplement | Pages: 3132-3132

10.1158/1538-7445.am2019-3132 Get It

Abstract Background: The level of immune suppression in an individual breast cancer (BC) patient is relevant for having a major benefit from treatments that act via or are directed to the immune response, such as anti-HER2 agents and immune checkpoint molecules, respectively. The link(s) between the tumor immune microenvironment and treatment responses has been investigated in HER2-positive BC. This study analyzed the association between baseline expression of genes regulating T cell activities (PD1, CTLA4, LAG3, TIM3, PDL1, PDL2, FOXP3, IL10, TGFβ (1-3), FOXP1 and other related genes) and pathologic complete response (pCR) rates in the NeoALTTO trial. Methods: NeoALTTO randomized early-stage HER2-positive BC patients to neoadjuvant trastuzumab (T), lapatinib (L) or T+L for 6 weeks followed by 12 weeks of concurrent paclitaxel. Anthracyclines were given after surgery (FEC). Patients with RNA sequencing data from their baseline tumor samples (N=254 patients out of 455 from the original cohort) were included in the current study. The primary endpoint, pCR, was defined as ypT0/is ypN0. Logistic regression was used for analysis of pCR. Cox regression univariate and multivariate (adjusted for clinicopathological parameters and treatment arms) analyses were performed. Results: In the total cohort analyzed, high PD1 (odds ratio, OR: 1.4, P=0.03), PDL2 (OR: 1.4, P=0.04), CTLA4 (OR: 1.4, P=0.03) and TGFβ3 (OR: 1.4, P=0.02) expression was associated with an increased probability of achieving pCR at the multivariate analysis. ERBB2 (HER2) expression was associated with pCR in the three arms (T: OR: 2.7, P=0.02; L: OR: 2.3, P=0.01; T+L: OR: 5, P<0.001). Additionally in the T+L arm, PAM50 HER2-enriched subtype (OR: 2.9, P=0.03), as well as immune genes PD1 (OR: 2.1, P=0.01), PDL1 (OR: 1.8, P=0.03) and CTLA4 (OR: 2; P=0.01), were also associated with pCR. Conclusions: In the NeoALTTO population examined, PD1, PDL2, CTLA-4 and TGFβ3 expression at diagnosis were all associated with improved pCR rates after anti-HER2 treatment. The effect of these treatments seemed to be dependent on HER2 expression levels, which was particularly relevant in the T+L arm. These observations confirm previous findings that link immune infiltrates to higher pCR rates, demonstrate the clinical significance of the PD-1 pathway and additionally show that CTLA-4 and TGFβ3 could also be important in early stage HER2-positive BC. The association of tumors linked with immune regulatory gene expression with positive responses to neoadjuvant anti-HER2 agents suggests that they act in a way that reinvigorates the antitumor immunity in the face of tumor-mediated suppression. Patients whose tumors highly express these genes may be good candidates for immunotherapy before the start or after the neoadjuvant treatment when residual disease is detected at surgery, although these hypotheses require further confirmation. Citation Format: Cinzia Solinas, Pushpamali De Silva, David Venet, Soizic Garaud, Chunyan Gu-Trantien, Florentine Hilbers, Evandro de Azambuja, Olena Werner, Lorena De la Peña, Amylou Dueck, Serena Di Cosimo, Istvan Lang, Jens Huober, Sherko Küemmel, Carsten Denkert, Roberto Salgado, Christos Sotiriou, Martine Piccart-Gebhart, Debora Fumagalli, Karen Willard-Gallo. Immune regulatory gene expression and clinical outcome in the NeoALTTO trial [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 3132.
ICAR: endoscopic skull‐base surgery
Zanation, Adam M., Gardner, Paul A. , Schwartz, Theodore H. , Eloy, Jean Anderson , Adappa, Nithin D. , Bettag, Martin, Casiano, Roy R. , Cavallo, Luigi Maria , Ebert, Charles S. , Evans, James J., Fernandez‐Miranda, Juan C. , Folbe, Adam J. , Froelich, Sébastien , Gentili, Fred, Harvey, Richard J. , Hwang, Peter H. , Jane, John A. , Kennedy, David W. , Knosp, Engelbert, Lee, John Y. K. , Lund, Valerie J. , Prevedello, Daniel M. , Schlosser, Rodney J. , Sindwani, Raj , Solares, C. Arturo , Tabaee, Abtin, Teo, Charles , Thirumala, Parthasarathy D. , Thorp, Brian D. , Vellutini, Eduardo de Arnaldo Silva , Witterick, Ian , Woodworth, Bradford A. , Wormald, Peter‐John , Mukherjee, Debraj , Wang, Eric W , Eloy, Jean Anderson , Lal, Devyani , Schlosser, Rodney J , Mukherjee, Debraj , Harvey, Richard J , Hwang, Peter H , Prevedello, Daniel M , Adappa, Nithin D. , Bleier, Benjamin S. , Cappabianca, Paolo , Carrau, Ricardo L. , El‐Sayed, Ivan H. , Kelly, Daniel F. , Lal, Devyani , Liu, James K. , Snyderman, Carl H

Mayo Clinic

International Forum of Allergy & Rhinology | July 22, 2019 | Volume: 9 | Issue: S3 | Pages: No page available

10.1002/alr.22326 | PMID 31329374 Get It

Background Endoscopic skull‐base surgery (ESBS) is employed in the management of diverse skull‐base pathologies. Paralleling the increased utilization of ESBS, the literature in this field has expanded rapidly. However, the rarity of these diseases, the inherent challenges of surgical studies, and the continued learning curve in ESBS have resulted in significant variability in the quality of the literature. To consolidate and critically appraise the available literature, experts in skull‐base surgery have produced the International Consensus Statement on Endoscopic Skull‐Base Surgery (ICAR:ESBS). Methods Using previously described methodology, topics spanning the breadth of ESBS were identified and assigned a literature review, evidence‐based review or evidence‐based review with recommendations format. Subsequently, each topic was written and then reviewed by skull‐base surgeons in both neurosurgery and otolaryngology. Following this iterative review process, the ICAR:ESBS document was synthesized and reviewed by all authors for consensus. Results The ICAR:ESBS document addresses the role of ESBS in primary cerebrospinal fluid (CSF) rhinorrhea, intradural tumors, benign skull‐base and orbital pathology, sinonasal malignancies, and clival lesions. Additionally, specific challenges in ESBS including endoscopic reconstruction and complication management were evaluated. Conclusion A critical review of the literature in ESBS demonstrates at least the equivalency of ESBS with alternative approaches in pathologies such as CSF rhinorrhea and pituitary adenoma as well as improved reconstructive techniques in reducing CSF leaks. Evidence‐based recommendations are limited in other pathologies and these significant knowledge gaps call upon the skull‐base community to embrace these opportunities and collaboratively address these shortcomings.
SUN-353 Adrenocortical Carcinoma: A Single Institution Experience in Mexico
Silva-Serrano, Juanita, Rosas‐Camargo, Vanessa, Iñiguez‐Ariza, Nicole M.

Mayo Clinic

Journal of the Endocrine Society | May 10, 2019 | Volume: 3 | Issue: Supplement_1 | Pages: No page available

10.1210/js.2019-sun-353 Get It

Stereotactic radiosurgery for idiopathic glossopharyngeal neuralgia: an international multicenter study
Kano, Hideyuki , Urgošík, Dušan, Liščák, Roman , Pollock, Bruce E. , Cohen‐Inbar, Or , Sheehan, Jason P. , Barnett, Gene H. , Mathieu, David , Sisterson, Nathaniel , Lunsford, L. Dade , Mathieu, David , Sharma, Mayur , Silva, Danilo

Mayo Clinic

Journal of Neurosurgery | April 19, 2019 | Volume: 125 | Issue: Supplement_1 | Pages: 147-153

10.3171/2016.7.gks161523 | PMID 27903192 Get It

OBJECTIVEThe goal of this study was to evaluate the outcomes of Gamma Knife stereotactic radiosurgery (SRS) when used for patients with intractable idiopathic glossopharyngeal neuralgia.METHODSSix participating centers of the International Gamma Knife Research Foundation identified 22 patients who underwent SRS for intractable glossopharyngeal neuralgia between 1998 and 2015. The median patient age was 60 years (range 34–83 years). The median duration of symptoms before SRS was 46 months (range 1–240 months). Three patients had unsuccessful prior surgical procedures, including microvascular decompression (MVD) (n = 2) and balloon compression (n = 1). The radiosurgical target was the glossopharyngeal meatus. The median maximum dose was 80 Gy.RESULTSThe median follow-up was 45 months after SRS (range 6–120 months). Twelve patients (55%) had < 4 years of follow-up. Thirteen patients (59%) had initial complete pain relief at a median of 12 days after SRS (range 1–60 days). Three patients (14%) had partial pain relief at a median of 70 days after SRS (range 60–90 days). Six patients (27%) had no pain relief. Among 16 patients with initial pain relief, 5 maintained complete pain relief without medication (Barrow Neurological Institute [BNI] pain intensity score Grade I), 1 maintained occasional pain relief without medication (BNI Grade II), 3 maintained complete pain relief with medication (BNI Grade IIIb), and 7 patients had pain recurrence at a median of 20 months after SRS (range 6–120 months). The rates of maintenance of adequate pain relief (BNI Grades I–IIIb) were 63% at 1 year, 49% at 2 years, 38% at 3 years, 38% at 5 years, and 28% at 7 years. When 7 patients without pain recurrence within 4 years of follow-up were excluded, the rates of maintenance of adequate pain relief were 38% at 5 years and 28% at 7 years. Ten patients required additional procedures (MVD, n = 4; repeat SRS, n = 5; glossopharyngeal nerve block, n = 1). Four of 5 patients who underwent repeat SRS maintained pain relief (BNI Grade I, n = 3; and BNI Grade IIIb, n = 1). No adverse effects of radiation were observed after a single SRS. Two patients developed hyperesthesia in the palatoglossal arch 5 and 8 months after repeat SRS, respectively.CONCLUSIONSStereotactic radiosurgery for intractable, medically refractory glossopharyngeal neuralgia provided lasting pain reduction in 55% of patients after 1 or 2 SRS procedures. Patients who had a poor response or pain recurrence may require additional procedures such as repeat SRS, MVD, nerve blocks, or nerve section. No patient developed changes in vocal cord function or swallowing disorders after SRS in this study.
White matter hyperintensities in vascular contributions to cognitive impairment and dementia (VCID): Knowledge gaps and opportunities
Alber, Jessica , Alladi, Suvarna , Barton, David A., Bell, Joanne M., Berman, Sara E., Biessels, Geert Jan , Bos, Isabelle , Bowman, Gene L. , Brai, Emanuele , Callahan, Brandy L. , Corriveau, Roderick A. , Fossati, Silvia , Gottesman, Rebecca F. , Gustafson, Deborah , Hachinski, Vladimir , Hayden, Kathleen M. , Helman, Alex M., Hughes, Timothy M. , Isaacs, Jeremy D. , Jefferson, Angela L. , Kern, Silke , Kwon, Jay C., Lee, Athene , Lockhart, Samuel N. , Murray, Anne M. , Osborn, Katie E. , Price, Brittani R. , Rhodius‐Meester, Hanneke , Rondeau, Jacqueline A., Rosen, Allyson , Scholtzova, Henrieta , Shaaban, C. Elizabeth , Silva, Nárlon Cássio Boa Sorte , Snyder, Heather M. , Swardfager, Walter , Troen, Aron M. , Vemuri, Prashanthi , Wallin, Anders , Wellington, Cheryl L. , Xie, Sharon X. , Hainsworth, Atticus H. , Vemuri, Prashanthi , Gottesman, Rebecca F , Hainsworth, Atticus H , Bae, Hee‐Joon , Beckett, Laurel , Biessels, Geert Jan , Black, Sandra E. , Brickman, Adam M. , Johnson, Sterling C. , Kapasi, Alifiya , Kukolja, Juraj , Power, Melinda C. , Rosene, Douglas L , Schneider, Julie A. , Veluw, Susanne J. van , Wilcock, Donna M.

Mayo Clinic

Alzheimer's & Dementia: Translational Research & Clinical Interventions | April 8, 2019 | Volume: 5 | Issue: 1 | Pages: 107-117

10.1016/j.trci.2019.02.001 | PMID 31011621 Get It

Abstract White matter hyperintensities (WMHs) are frequently seen on brain magnetic resonance imaging scans of older people. Usually interpreted clinically as a surrogate for cerebral small vessel disease, WMHs are associated with increased likelihood of cognitive impairment and dementia (including Alzheimer's disease [AD]). WMHs are also seen in cognitively healthy people. In this collaboration of academic, clinical, and pharmaceutical industry perspectives, we identify outstanding questions about WMHs and their relation to cognition, dementia, and AD. What molecular and cellular changes underlie WMHs? What are the neuropathological correlates of WMHs? To what extent are demyelination and inflammation present? Is it helpful to subdivide into periventricular and subcortical WMHs? What do WMHs signify in people diagnosed with AD? What are the risk factors for developing WMHs? What preventive and therapeutic strategies target WMHs? Answering these questions will improve prevention and treatment of WMHs and dementia.
053. CLINICAL UTILITY OF SERIAL MEASUREMENTS OF ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES TARGETING PROTEINASE 3 IN ANCA-ASSOCIATED VASCULITIS
Thompson, Gwen , Fussner, Lynn A. , Hummel, Amber M., Snyder, Melissa, Kallenberg, Cees G. M., Langford, Carol A. , Clair, E. William St. , Stone, John H. , Schroeder, Darrell R. , Silva, Francisco , Snyder, Melissa, Merkel, Peter A. , Monach, Paul A. , Seo, Philip , Spiera, Robert , Specks, Ulrich

Mayo Clinic

Rheumatology | March 29, 2019 | Volume: 58 | Issue: Supplement_2 | Pages: No page available

10.1093/rheumatology/kez057.052 Get It